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Genome-wide DNA methylation 
changes in CD19+ B cells from 
relapsing-remitting multiple 
sclerosis patients
Vicki E. Maltby  1,2, Rodney A. Lea1,3, Moira C. Graves1,2, Katherine A. Sanders2,4, 
Miles C. Benton  1,3, Lotti Tajouri4, Rodney J. Scott2,5,6 & Jeannette Lechner-Scott1,2,7
Multiple Sclerosis (MS) is an inflammatory and neurodegenerative disease of the central nervous 
system. The inflammatory process in MS is driven by both T and B cells and current therapies are 
targeted to each of these cell types. Epigenetic mechanisms may provide a valuable link between genes 
and environment. DNA methylation is the best studied epigenetic mechanism and is recognized as a 
potential contributor to MS risk. The objective of this study was to identify DNA methylation changes 
associated with MS in CD19+ B-cells. We performed an epigenome-wide association analysis of DNA 
methylation in the CD19+ B-cells from 24 patients with relapsing-remitting MS on various treatments 
and 24 healthy controls using Illumina 450 K arrays. A large differentially methylated region (DMR) 
was observed at the lymphotoxin alpha (LTA) locus. This region was hypermethylated and contains 
19 differentially methylated positions (DMPs) spanning 860 bp, all of which are located within the 
transcriptional start site. We also observed smaller DMRs at 4 MS-associated genes: SLC44A2, LTBR, 
CARD11 and CXCR5. These preliminary findings suggest that B-cell specific DNA-methylation may be 
associated with MS risk or response to therapy, specifically at the LTA locus. Development of B-cell 
specific epigenetic therapies is an attractive new avenue of research in MS treatment. Further studies 
are now required to validate these findings and understand their functional significance.
Multiple Sclerosis is an inflammatory and neurogenerative disease leading to demyelination and axonal loss. Risk 
of developing MS is thought to be influenced by both genetic and environmental factors. The primary environ-
mental factors that influence disease pathology are sunlight exposure, Epstein-Barr virus (EBV) infection and 
smoking1. Genome wide association studies (GWAS) have identified 149 genes associated with MS risk with 
approximately one third coming from variations in the major histocompatibility complex (MHC)2,3. Despite this, 
there still remains a large element of unexplained heritability in terms of disease pathology.
Epigenetic mechanisms are capable of modifying the genome without changes to the DNA sequence and can 
be inherited. One well-studied epigenetic mechanism is DNA methylation, which is the addition of a methyl 
group to CpG dinucleotides. We, and others, have used genome-wide DNA methylation technologies to identify 
differentially methylated positions (DMPs) in the T-cells of MS patients compared to healthy controls4–8. In two 
independent studies of CD4+ T-cells, we found a striking differentially methylated region (DMR) located within 
the major histocompatibility complex (MHC) region, with a major peak at HLA-DRB1 and RNF394,6. Using the 
same cohort of patients we assessed DMPs in CD8+ T-cells and found 79 DMPs, all of which showed minor asso-
ciation with MS but none of which overlapped with any of the DMPs found in CD4+ T-cells5. A study by Bos et al. 
also found little overlap between the methylation profiles of CD4+ and CD8+ T-cells, highlighting the importance 
of investigating individual cell subtypes.
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There is evidence to suggest that T-cells may have a role in MS pathology (reviewed in Martin et al.9). However, 
it is becoming increasingly clear that B-cells may also play a substantial role in helping to drive disease. Activated 
B-cells may contribute to MS pathology as antibody producing cells, antigen presenting cells or as a source of 
pro-inflammatory cytokines (reviewed in Lehmann-Horn et al.10). Evidence for this is in the success of B-cell 
depleting monoclonal antibodies, such as rituximab11 and ocrelizumab12 as MS therapies. Additionally, many 
currently approved MS therapies, for example fingolimod and dimethyl fumarate, also have an impact on B cells 
through reduced numbers or a shift in phenotype towards a more anti-inflammatory cytokine profile (reviewed 
in Lehmann-Horn et al.10).
In an effort to identify B-cell specific DMPs associated in MS, we performed genome-wide DNA methylation 
study of CD19+ B-cells from MS patients and healthy controls. We used the same cohort and data analysis tech-
niques as our previous studies so that the results could be compared to those from the CD4+ and CD8+ T-cells.
Methods and Materials
Ethics Statement. The Hunter New England Health Research Ethics Committee and University of 
Newcastle Ethics committee approved this study (05/04/13.09 and H-505-0607 respectively), and methods were 
carried out in accordance with institutional guidelines on human subject experiments. Written and informed 
consent was obtained from all patient and control subjects. MS patients gave written and verbal consent. The 
Australian Red Cross Blood Service ethics committee approved the use of blood from healthy donors.
Sample Processing. We performed an epigenome-wide association study (EWAS) of CD19+ B-cells using 
the same patient cohort, work flow and data analysis as described in our previous study4. Briefly, whole blood 
was collected from 24 RRMS patients and 24 healthy controls. All patients were diagnosed with RRMS according 
to the McDonald criteria13. PBMCs were isolated from 45 mL of whole blood by density gradient centrifugation 
on lymphoprep (StemCell Technologies, Canada). CD19+ B cells were isolated using positive selection, mag-
netic separation kits (Stem Cell Technologies, Canada) according to the manufacturer’s protocols. Purity was 
assessed using FITC conjugated anti-CD19 antibody (clone H1B19, catalog #60005FL.1, StemCell Technologies, 
Canada) and the FACS CantoII flow cytometer (BD Biosciences, USA) and analyzed using the FACSDiva software 
(BD Biosciences, USA). All samples met a minimum purity threshold of ≥90%. DNA was extracted using the 
QiaAMP DNA micro kit (Qiagen, USA). DNA was then bisulphite converted and hybridized to Illumina 450 K 
arrays (service provided by the Australian Genome Research Facility).
Data analysis. Raw fluorescence data were processed using a combination of R/Bioconductor and custom 
scripts. Raw data was parsed into the Bioconductor MINFI package. Methylation data was background corrected 
and quantile normalized according to MINFI routines. Data was cleaned by removing control probes, probes 
which map multiple times to the genome, cross-reactive probes and failed probes for which the intensity of both 
the methylated and the unmethylated probes was <1000 units across all samples. A threshold of 1000 units was 
selected based on the profile of the available negative control probes. Y chromosome probes were filtered out. All 
probe sequences were mapped to the human genome (buildHg19) using BOWTIE14 to identify potential hybrid-
ization anomalies. We chose to retain probes containing single nucleotide polymorphisms (SNPs) and filter these 
out post hoc where appropriate (see results section).
Measures of methylation (β values) were produced for each probe and ranged from completely unmethylated 
(β = 0) to completely methylated (β = 1). To identify differentially methylated positions (DMPs) associated with 
MS subtypes in this cohort, we first calculated the difference in median β value by subtracting the median β value 
of controls (mediancont) from the median β value for cases (mediancase). This produced a Δmeth score ranging 
from −1 (hypomethylated) to 1 (hypermethylated). A two-sample Kolmogorov-Smirnov test (K-S test) was used 
to determine if Δmeth was statistically significant. A K-S test was chosen over the F test because of the marked 
variation in the distribution of the β values among the probes. Rather than base our CpG selection strictly on 
statistical significance (P-values) of the K-S test, which is overly limiting due to the small sample size and could 
miss important signal, we used a selection strategy based on a combination of P-value and effect size (ie. Δmeth 
score). We have used this approach successfully in previous studies to implicate differential methylation at HLA 
in CD4+ cells with regard to MS4–6. A CpG was considered a DMP if the P-value was <0.05 and the absolute β 
value was >±0.1. Differentially methylated regions (DMRs) were called if at least two DMPs were found within 
a 500 base pair (bp) span of each other and were altered in the same direction (either all hypermethylated or all 
hypomethylated).
Over-Representation Analysis (ORA): To assess the biological relevance of DMPs in terms of MS pathology 
we conducted an ORA on resultant the DMP list using the WebGestalt engine (www.webgestalt.org) incorporat-
ing the KEGG pathways database.
Results
DMP and DMR analyses. Table 1 shows the patient demographic for 24 MS patients and 24 healthy controls 
(Table 1). A total of 7618 CpGs met the criteria for a DMP (Table S1). Figure 1 shows the genome-wide distribu-
tion of differential methylation (Δmeth) for all DMPs. Amongst the DMPs, we observe an overall hypomethylation 
in MS cases, with 4731 (62%) of DMPs being hypomethylated and 2887 (38%) being hypermethylated in MS 
patients versus controls. When we considered genomic features for all DMPs we found 1869 (24.5%) map to 
intergenic regions, 3226 (42.3%) within the gene body, 1254 at the transcriptional start site (TSS1500 or TSS200) 
(16.5%), 699 in the 5′ untranslated region (UTR) (9.2%), 211 map to the 1st exon (2.8%) and 359 in the 3′UTR 
(4.7%) (Fig. 2).
DMPs were ranked by Δmeth values. The two top ranked DMPs were located within the lymphotoxin alpha 
(LTA) gene (alias: tumor necrosis factor beta, TNFβ - hereafter referred to as LTA). These two sites had Δmeth 
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values of 0.504 and 0.486 (50.4% and 48.6% hypermethylated respectively) in the MS patient group compared to 
the control group (P < 0.0001). Of the CpGs that met the criteria for a DMP, 19 are found in the LTA locus within 
a region of 860 bp. All sites are hypermethylated with Δmeth scores between 0.15 and 0.5 (between 15% and 50%) 
and are located within the TSS/5′UTR (Table 2).
Genetic influence at the LTA locus. One technical limitation of array technology is the influence that 
SNPs may have on the calculated methylation levels (β values). Of the 19 DMPs identified at the LTA TSS, 13 
of the corresponding probes contain an adjacent SNP which may potentially influence the methylation profile 
(Table 2). Rather than remove these sites from our analysis, we assessed the genetic influence on the methylation 
signal by visualizing the distribution of β values.
Figure 3A shows an example of a CpG site whose methylation signal is known to be influenced by a SNP 
located at this probe. This example shows that the β values cluster into 3 distinct regions representing the 3 possi-
ble genotypes (homozygous allele 1, homozygous allele 2 or heterozygous). Figure 3B shows the influence of SNPs 
on the top LTA CpG site in our DMR. The β values form a uniform spread, providing support that the SNP is not 
influencing the methylation signal at this particular CpG site. A similar result is seen in all DMPs within the LTA 
cluster (data not show). In addition to this, we compared the profiles of LTA in CD4+ and CD8+ T-cells from our 
previous data sets with the same cohort. We found that hypermethylation at the LTA TSS appears to be specific to 
CD19+ B-cells, providing further support that the methylation effects observed in this cohort are at least partially 
exclusive from the underlying genotype (Fig. 4).
Figure 1. A genome-wide differential methylation plot. Data points outside the circle (red) represent increased 
methylation (i.e. ∆meth), in multiple sclerosis (MS) patients compared to controls whereas points inside the circle 
(blue) represent decreased methylation in MS patients compared to healthy controls.
Characteristic
MS participant 
(n = 24) Control (n = 24)
Age range (yrs) 40.7 ± 8.5 43.3 ± 16.4
EDSS 2.4 ± 1.3
Disease duration (yrs) 9.3 ± 6.6
Treatment (n)
  • Naïve 1
  • OFF > 3 months 4
  • Interferon beta-1b 2
  • Interferon beta-1a 3
  • Glatiramer acetate 2
  • Natalizumab 4
  • Fingolimod 8
Table 1. Subject demographics.
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Differential methylation at other genes within the MHC locus. Our previous study in CD4+ T-cells 
identified a peak of differential methylation on chromosome 6 that mapped to the MHC region4. Specifically, we 
found a differentially methylated region that spanned 11 sites at the well-established MS risk gene, HLA-DRB1 
that was unique to CD4+ T-cells4,5. To determine if there is any overlap of DMPs in the MHC region between 
CD4+ T-cells and CD19+ B-cells, we performed a closer analysis of the MHC region. Figure 5 shows that although 
a similar distinct peak is present at the MHC region, it corresponds primarily to the DMR at LTA and to a lesser 
extent HLA-DRB1. However, there are 4 DMPs in CD19+ B-cells that overlap with the sites found in CD4+ T-cells 
(Table 3). These sites correspond to probes cg04985482, cg06032479, cg17416722, and cg24147543. The first site 
maps to the MHC class I polypeptide related sequence A (MICA) locus and the remaining three sites all map to 
sites within HLA-DRB1. All sites are altered in the same direction (hypo- or hypermethylated) and have a similar 
differential methylation value in both cell subsets (Table 3).
Differential methylation at sites outside the MHC locus. To explore the importance of methylation 
outside the MHC region, we filtered DMPs outside the MHC to include only those contained within the TSS 
or 5′UTR (1953 DMPs). We chose the TSS and 5′UTR as an initial filtering step because DNA methylation that 
occurs in the promoter regions is generally associated with transcriptional repression, but its role elsewhere in 
Figure 2. Distribution of DMPs over each of the genomic regions Y-axis represents proportion of total DMPs 
(7618) in each category (shown as percentage).
IlmnID MAPINFO Element Gene Probe SNP
Probe 
SNPs10
mean 
MS
mean 
HC Δmeth P value
cg10995925 31539601 TSS1500 LTA 0.68 0.50 0.18 4.06E-04
cg14441276 31539735 TSS1500;TSS200 LTA rs56161754 0.59 0.20 0.39 4.06E-04
cg09621572 31539973 TSS200;1stExon;5′UTR LTA rs36221306 rs56018225 0.66 0.24 0.42 4.57E-06
cg14437551 31539986 TSS200;1stExon;5′UTR LTA rs36221306 0.70 0.19 0.50 1.04E-04
cg14597739 31539998 TSS200;1stExon;5′UTR LTA rs56207507 rs36221306 0.74 0.25 0.49 1.04E-04
cg16219283 31540002 TSS200;1stExon;5′UTR LTA rs56207507 0.72 0.30 0.42 1.04E-04
cg21999229 31540014 TSS200;1stExon;5′UTR LTA rs56207507 0.65 0.27 0.39 2.34E-05
cg17169196 31540026 TSS200;1stExon;5′UTR LTA rs36221309 rs56207507 0.71 0.36 0.35 2.34E-05
cg02402436 31540051 TSS200;1stExon;5′UTR LTA rs36221309 0.47 0.18 0.29 4.57E-06
cg09736959 31540114 5′UTR LTA rs2239704 0.62 0.33 0.29 1.40E-03
cg24216966 31540121 5′UTR LTA rs2239704 0.73 0.38 0.35 1.04E-04
cg11586857 31540136 5′UTR LTA rs56245447 rs2239704 0.75 0.45 0.30 1.04E-04
cg10476003 31540169 5′UTR LTA rs56245447 0.55 0.29 0.25 4.57E-06
cg01157951 31540399 5′UTR LTA 0.42 0.23 0.19 2.34E-05
cg22318806 31540411 5′UTR LTA rs4986978 0.41 0.23 0.18 4.06E-04
cg13815684 31540440 5′UTR LTA 0.73 0.42 0.30 1.04E-04
cg17709873 31540456 5′UTR LTA 0.53 0.38 0.15 4.32E-03
cg16280132 31540459 5′UTR LTA 0.49 0.31 0.18 1.04E-04
cg26348243 31540461 5′UTR LTA 0.47 0.20 0.28 2.34E-05
Table 2. DMR at LTA. IlmnID = Illumina ID; MapINFO = genomic coordinates (Hg19); Element from UCSC 
RefGene; Probe SNP; Probe SNPs10.
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the genome is more complex and less well understood15. We then further filtered the list to include only DMRs. A 
DMR was considered if i) there were 2 or more DMPs, ii) these DMPs fell within a 500 bp span iii) the DMPs were 
altered in the same direction. This generated a list of 276 genes which contained a DMR in their 5′UTR or TSS.
A comparison of this list to genes with a known association to MS2,3,16–18 revealed 4 DMRs (Table 4). Choline 
transporter-like 2 (SLC44A2) and Lymphotoxin β receptor (LTBR) each have 2 hypomethylated DMPs within 
their TSS/5′UTR which are 72 and 113 bp apart, respectively. Caspase recruitment domain-containing protein 11 
(CARD11) has 2 DMPs at the 5′UTR. Both of which are hypermethylated and 101 bp apart. There is a third DMP 
which is hypermethylated at the 5′UTR of CARD11; however, it is located >62,000 bp downstream of the DMR so 
it did not fulfil the criteria to be part of the DMR. At the TSS of the CXC chemokine receptor 5 (CXCR5), there are 
2 DMRS that are 9266 bp apart. The first of these has 5 hypermethylated DMPs within an 86 bp span. These DMPs 
are between 20.7% and 31.1% hypermethylated. The second contains 3 DMPs within 42 bp of each other that are 
17.7%, 13.9% and 18% hypermethylated.
Further analysis revealed several other DMRs outside the MHC region which reside in genes that may have 
biological significance to MS pathology. Of interest, there are 5 DMPs which lie within a 269 bp span at the 
cluster of differentiation 19 (CD19) locus. All are found within the TSS or 5′UTR and are hypermethylated by 
22.4–30.7%. There is also a DMR at interleukin 21 receptor (IL21R) where 4 hypermethylated DMPs lie within a 
264 bp span at the TSS.
Over-Representation Analysis (ORA). The 7618 DMPs identified in the methylation analysis were 
located in 2899 genes. To assess the biological relevance of this gene set in terms of MS pathology we conducted a 
ORA using the WebGestalt engine to identify potential pathways associated with the 2899 gene set. Pathway anal-
ysis revealed significant alignment to innate immune system (293 genes, P = 4.08E-09), B-cell receptor signaling 
pathway (28 genes, P = 3.31E-04), cytokine signaling in Immune system (166 genes, 4.14E-04), and signaling by 
interleukins (119 genes, 1.46E-03). Table 5 shows the top 10 pathways identified.
Discussion
B-cells are gaining recognition in MS as potential regulators of disease pathology. In this study, we are the first to 
describe changes in the global DNA methylation profile in the CD19+ B-cells of MS patients compared to healthy 
controls. We find a slight overall hypomethylation and enrichment of genes involved in innate immunity and 
B-cell receptor and cytokine signaling pathways. We have identified a large, hypermethylated DMR in the TSS of 
LTA that is unique to the B-cell population. In addition, we identified four smaller DMRs at genes which contain 
known MS-associated SNPs, SLC44A2, LTBR, CXCR5, and CARD11.
The large DMR at LTA is of interest due to its longstanding, strong associations with MS. LTA encodes for the 
pro-inflammatory cytokine lymphotoxin-alpha (LT-α). LTA is over-expressed in CD4+ T-cells, CD8+ T-cells 
and CD19+ B-cells of RRMS patients19. Furthermore, in RRMS patients the LTA CSF/PBMC expression ratios 
are increased, and positively correlate with CD19 expression in CSF cells19. LTA producing cells have been found 
in the immediate vicinity of the demyelinating process in MS patients20 and expression is present in acute and 
Figure 3. Tukey box plot showing distribution of beta values for (A) a probe where the SNP is driving the 
methylation values and (B) the top LTA site from this study. The box plot shows the data within the interquartile 
range and the median is represented by a solid black line. Whiskers show maximum and minimum values. Grey 
bars indicate region for each genotype (homozygous allele 1 (1/1), heterozygous (1/2), and homozygous allele 2 
(2/2)). Each point represents either an individual control (blue) or MS patients (red). Y axis shows β values.
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chronic active brain lesions in MS patients21. One inconsistency is that we have shown hypermethylation in the 
TSS, which implies potential downregulation of transcription (as opposed to over-expression). The most likely 
explanation for this inconsistency is the presence of hydroxymethylation. Bisulfite conversion does not distin-
guish between hydroxymethylated and methylated sites; thus, both are considered methylated by the methods 
Figure 4. DMPs within the LTA TSS/5′UTR region Line graph showing the methylation level (β value) of MS 
cases (blue) versus controls (red) for the genomic region 31539601-31540461 for (A) CD19+ B cells (B) CD4+ T 
cells4,6 and (C) CD8+ T cells5. The region covers 19 probes contained within the LTA gene.
Figure 5. Methylation at the MHC locus in CD19+ B cells Manhattan plot showing methylation level 
(Δmeth) for all probes that fall within the MHC locus (Chr6: 29054321-32978719). Points above 0 represent 
hypermethylated sites, points below 0 represent hypomethylated sites. Grey dotted line indicates 10% change in 
methylation.
www.nature.com/scientificreports/
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used in this study. Unlike methylation, which negatively correlates with transcription, hydroxymethylation has 
been found to positively correlate with active transcription22–25. Therefore, it is plausible that the methylation 
changes at LTA are due to changes in hydroxymethylation which would result in the overexpression seen in pre-
vious studies.
Another explanation for the inconsistency between our findings and previous studies could be due to tran-
script variants. LTA is known to have eight transcript variants, with multiple start sites26. Thus, the hypermethyl-
ation seen in our study may be related to an alternate transcriptional variant to that identified in previous studies. 
Alternately, previous studies were conducted primarily in treatment naïve patients, whereas our cohort only con-
tains 1 treatment naïve sample. Therefore, hypermethylation and decreased LTA expression may be a result of 
treatment effects, or simply be reflective of disease stabilization.
Although we find DMRs at four other genes previously associated with MS, the functional significance of 
these DMRs is unclear. SLC44A2 is found in the peripheral tissues and has been associated with thrombosis and 
autoimmune hearing loss but not MS27. CXCR5 is used as the defining marker for follicular B helper T-cells (TFH) 
but its expression has not been demonstrated in B-cells28.
A recent study found LTBR expression levels increased in the animal model of MS, experimental autoimmune 
encephalitis (EAE), and that blockage of this receptor ameliorated disease in mice29. The same study investi-
gated LTBR expression in RRMS patients and found increased transcript levels in patients who were resistant to 
IlmnID CHR MAPINFO Gene
CD4 CD19
mean 
MS
mean 
HC Δmeth P value
mean 
MS
mean 
HC Δmeth P value
cg04985482 6 31382065 MICA 0.72 0.84 −0.12 9.93E-03 0.73 0.84 −0.11 2.99E-02
cg06032479 6 32552026 HLA-DRB1 0.65 0.75 −0.10 7.00E-03 0.65 0.78 −0.13 1.20E-02
cg17416722 6 32554385 HLA-DRB1 0.38 0.07 0.31 1.02E-03 0.28 0.06 0.22 1.40E-03
cg24147543 6 32554481 HLA-DRB1 0.47 0.34 0.14 6.44E-04 0.28 0.12 0.16 1.20E-02
Table 3. Common sites at the MHC locus in CD4 and CD19. Data from CD4+ T cells from Graves, M. C. et al. 
and Maltby, V. E. et al.4,6.
IlmnID CHR MAPINFO Gene
mean 
MS
mean 
HC Δmeth P value Element
cg24041556 19 10736059 SLC44A2 0.59 0.69 −0.10 2.99E-02 TSS200;Body
cg06561886 19 10736299 SLC44A2 0.69 0.80 −0.11 1.40E-03 5′UTR;1stExon;Body
cg24621362 12 6492890 LTBR 0.13 0.23 −0.10 2.34E-05 TSS1500
cg23079808 12 6493003 LTBR 0.13 0.23 −0.10 1.20E-02 TSS1500
cg19014792 7 3019159 CARD11 0.52 0.32 0.20 4.32E-03 5′UTR
cg16495448 7 3019260 CARD11 0.38 0.22 0.15 1.20E-02 5′UTR
cg14168009 7 3082006 CARD11 0.69 0.42 0.27 4.06E-04 5′UTR
cg16235962 11 118754507 CXCR5 0.60 0.32 0.28 1.04E-04 TSS200
cg04625873 11 118754530 CXCR5 0.56 0.36 0.21 1.20E-02 TSS200
cg25087423 11 118754535 CXCR5 0.71 0.39 0.31 1.20E-02 TSS200
cg26164712 11 118754565 CXCR5 0.61 0.35 0.25 4.32E-03 5′UTR;1stExon
cg16280667 11 118754593 CXCR5 0.61 0.34 0.27 4.06E-04 5′UTR;1stExon
cg04537602 11 118763859 CXCR5 0.62 0.44 0.18 1.04E-04 Body;TSS1500
cg13298528 11 118763863 CXCR5 0.68 0.54 0.14 2.34E-05 Body;TSS1500
cg19791714 11 118763901 CXCR5 0.53 0.35 0.18 4.57E-06 Body;TSS200
cg07597976 16 28943019 CD19 0.55 0.24 0.31 4.06E-04 TSS1500
cg06323049 16 28943094 CD19 0.62 0.33 0.29 1.20E-02 TSS200
cg27565966 16 28943198 CD19 0.68 0.39 0.29 1.40E-03 TSS200
cg05433111 16 28943232 CD19 0.49 0.25 0.24 1.40E-03 TSS200
cg01758575 16 28943288 CD19 0.53 0.31 0.22 4.32E-03 1stExon;5′UTR
cg16454902 16 27414272 IL21R 0.25 0.15 0.10 1.40E-03 TSS200;5′UTR
cg02513379 16 27414281 IL21R 0.28 0.14 0.14 4.57E-06 TSS200;5′UTR
cg00050618 16 27414418 IL21R 0.73 0.50 0.23 2.34E-05 TSS200;5′UTR
cg02787852 16 27414536 IL21R 0.67 0.40 0.27 1.06E-07 1stExon;5′UTR;5′UTR
cg10416668 16 27437730 IL21R 0.75 0.60 0.15 1.20E-02 TSS1500;5′UTR;5′UTR
cg25341726 16 28518331 IL27 0.37 0.50 −0.12 1.20E-02 TSS200
cg00201760 16 28518385 IL27 0.32 0.45 −0.13 1.20E-02 TSS1500
Table 4. DMRs outside the MHC locus.
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interferon beta (IFNβ) therapy29. Hypomethylation in the TSS may be correlated with increased transcription of 
LTBR; however, the study by Inoue and colleagues used PBMCs, which contain a mixture of T-cells and B-cells, 
so it remains to be elucidated if increased expression is occurring in B-cells.
Although CARD11 does not yet have a demonstrated, functional role in MS, it is an essential scaffolding 
platform for the CARD11/ BCL10/MALT1 (CBM) complex30. NFκB governs the BCR-induced (B cell receptor) 
NFκB activation through a complex series of phosphorylation events that results in destruction of the NFκB 
inhibitor, IκB30. One known mechanism of action of the common MS therapy, dimethyl fumarate, is inhibition of 
the NFκB transcription factor; therefore, an intriguing possibility is that dysregulation of this pathway may play 
a role in MS pathology31.
Although not part of the MHC locus or previously linked to MS, IL21R is involved in other autoimmune con-
ditions such as systemic lupus erythematosus (SLE)32 and arthritis33. It has been linked to B-cell proliferation and 
survival as well as B-cell apoptosis which suggesting a role in immune cell function34,35.
Autoimmune diseases often have overlapping aetiological and genetic backgrounds36. In our previous studies, 
we found that there is also overlap in epigenetic profiles of CD4+ T-cells from SLE and MS patients6. Recently, 
Julià et al.37 assessed the DNA methylation profiles of B-cells from rheumatoid arthritis (RA) patients and per-
formed a comparison with SLE patients37. To determine if there is overlap in the epigenetic profiles of CD19+ 
B-cells we compared our results to this study. Of the ten probes identified in their study, five also show differential 
methylation in the same direction (all hypermethylated) as in our study (Table 6). This suggests a common epige-
netic precursor or epigenetic effect among related autoimmune diseases.
One important consideration for our study is that the patients tested were taking various medications at the 
time of recruitment including interferons, glatiramer acetate, natalizumab and fingolimod. Only one patient was 
treatment naïve and 4 had been off treatment for more than 6 months. Although this study controlled for age, 
sex and treatment effects (as much as possible), due to our limited size we cannot control for changes associated 
with various environmental factors. Additionally, we were unable to control for B cell subtype compositions. As 
a third of the patients were taking fingolimod, this may have caused a significant change in the circulating cells.
This study adds to our knowledge of epigenetic factors in MS and further highlights the need to investigate 
individual cell subtypes when assessing DNA methylation in disease. It also raises several new and important 
questions including i) are these changes due to treatment effects ii) is the change in methylation at LTA due to 
hydroxymethylation iii) what role do environmental factors play on methylation changes iv) are the methylation 
effects due to changes in B cell subtypes and v) are DNA methylation changes a pre-disposing factor for MS or 
are they a result of disease pathology? Further studies are required using larger, treatment naïve cohorts that 
include epidemiological data will help extract if these results are due to treatment effects and allow the addition 
Pathway (BioSystems) Source
No. of 
genes
FDR 
P-value
Neutrophil degranulation REACTOME 138 9.20E-10
Innate Immune System REACTOME 293 4.08E-09
Hematopoietic cell lineage KEGG 40 8.88E-07
Hemostasis REACTOME 150 3.16E-05
Extracellular matrix organization REACTOME 80 1.54E-04
Signalling events mediated by focal adhesion kinase Pathway Interaction Database 24 1.97E-04
Phospholipase D signalling pathway KEGG 46 3.31E-04
B cell receptor signalling pathway KEGG 28 3.31E-04
Regulation of RAC1 activity Pathway Interaction Database 19 3.82E-04
Cytokine Signalling in Immune system REACTOME 166 4.14E-04
Table 5. Pathways Analysis of Genes with dysregulated DMPs.
CpG Chr Gene
RA (n = 65 
cases) Δmeth
SLE (n = 47 
cases) Δmeth
MS (n = 24 
cases) Δmeth
cg18972751 1 CD1C 5.7 3.4 5.3
cg09327855 1 NID1 1.3 1.1 10.2
cg03055617 3 TNFSF10 −6.9 −5.9
cg06613783 10 SKIDA1 2.7 1.6
cg07285641 13 DHRS12 1.7 1
cg01619562 14 ITPK1 3.4 1.03 3.8
cg01810713 16 IRF8 3.1 10.1
cg04033022 16 ACSF3 2.6 0.12 14.8
cg00253346 22 TNFRSF13C 2 1.4 8.1
cg08271031 22 PARVG 2.2 3
Table 6. Probes which are differentially methylated in RA, SLE and MS. Bold = differential methylation in all 
three diseases. Based on ref.36. Julia A. et al. Hum Mol Genet. 2017; 26(14):2803-11.
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of environmental factors such as vitamin D, EBV virus infection and smoking as covariates in the analysis. 
Additionally, further studies should attempt to extrapolate the relative effect of methylation versus hydroxymeth-
ylation, possibly using a more targeted approach such as next generation sequencing. Overall, our results suggest 
that B-cell specific epigenetics may play a role in MS pathology. B-cell specific epigenetic therapies which target 
LTA expression would therefore be an attractive new avenue of research in MS treatments.
Availability of Data and Material
The datasets generated or analyzed during the current study are included in this published article (Supplementary 
Table 1). Raw data files are available from Assoc. Prof. Rodney A. Lea.
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